Akari Therapeutics (NASDAQ:AKTX) Stock Price Crosses Below 200 Day Moving Average – Here’s What Happened

Akari Therapeutics, Plc (NASDAQ:AKTX)’s stock price passed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $2.72 and traded as low as $2.21. Akari Therapeutics shares last traded at $2.27, with a volume of 17,467 shares changing hands.

Wall Street Analysts Forecast Growth

Separately, StockNews.com initiated coverage on shares of Akari Therapeutics in a research note on Friday. They issued a “sell” rating on the stock.

Akari Therapeutics Stock Up 2.7 %

The stock has a fifty day moving average of $3.14 and a 200-day moving average of $2.72.

About Akari Therapeutics

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.